Page 2461 - Williams Hematology ( PDFDrive )

2432 Index Index 2433

Factor XIII (Cont.): FAT3, 1737 Felty syndrome, 996, 1203, 1565
structure, 1934, 2144 Fat aspiration, subcutaneous, 1776, 1776f FERMTS3, 2060
synthesis, 2144 Fatigue, history of, 4 Ferric iron, 619
Factor XIIIa, 2153 Fatty acid oxidation (FAO), 198, 200 Ferritin, 617–618
Factor XIII deficiency, 2143–2145 Fatty acyl translocase (FAT). See in anemia of inflammation, 552, 553f, 553t
clinical features, 2144–2145 Glycoprotein (GP)IV in hemophagocytic lymphohistiocytosis,
definition and history, 2144 Fatty marrow, 28 1115
gene mutations, 1935, 2135t, 2144 Fatty streak, 2286 in iron deficiency, 552, 553f, 553t, 634–635
incidence, 2133, 2134t Favism, 707, 709 in iron homeostasis, 623, 624f
therapy, 2136t, 2145 FBXW7, 231t, 1521 mitochondrial, 624, 919
Factor H, 2260 FcαR, 1161 Ferritin H chain, 621t
FADD (fas-associated death domain), 204f, Fcγ receptor I (FCγR1, CD64), 948, 1053, Ferrochelatase (FECH, heme synthetase),
205, 249, 302, 302f 1095, 1383 893f, 895, 917
Faggot cells, 1390 Fcγ receptor IIA (FcγRIIA, CD32) Ferrokinetics, 490–491, 490f, 491t
FAK (focal adhesion kinase), 266, 1841 in acute myelomonocytic leukemia, 1380t Ferroportin (SLC40A1, SLC11A3), 620, 621t,
FAM46C, 233t, 1736, 1736t, 1737, 1759 in heparin-induced thrombocytopenia, 642
Famciclovir, 386, 387t 2027, 2027f Ferroprotoporphyrin IX. See Heme
Familial deficiency of high-density in monocytes/macrophages, 1053 Ferruginous micelles, 466f, 468
lipoproteins, 684 in neutrophils, 1008, 1015–1016 Fetal blood, 102
Familial hemophagocytic in phospholipid metabolism, 1016 Fetal DNA, circulating cell-free, 852
lymphohistiocytosis (FHL), 1228, in platelets, 1856, 1869–1870 Fetal erythrocytes, 2336–2337
1849, 2061 Fcγ receptor III (FcγRIII, CD16) Fetal hemoglobin. See Hemoglobin F
Familial Mediterranean fever, 1024–1026 CD14 and, 1056 Fetal loss, 122–123
Familial neutropenia, 994 in monocytes, 1052 Fetus
Familial platelet disorder with predisposition in eosinophils, 949, 949t, 953 alloimmune hemolytic disease of. See
to acute myelogenous leukemia, expression, 1053 Alloimmune hemolytic disease of
2060 in monocytes, 1095 the fetus and newborn (HDFN)
Familial thrombocytosis, 1310 in natural killer cells, 1142, 1190 blood sampling, 854
Family history, 7 in neutrophils, 1008, 1015–1016 erythropoiesis in, 480
FANC, 1346t rituximab response and, 1794 hematolymphopoiesis in, 99–102, 100f,
Fanconi anemia, 527–530 structure, 1053, 1053f 101t, 102f
clinical features, 529 Fcγ receptors, 308, 953, 1009, 1063f, 2000 immunoglobulin in, 2347
clonal myeloid disorders and, 1345 FcγRII (CDw32), 953 intrauterine transfusion, 854–855
definition and history, 527 F cells, 730 Fever
differential diagnosis, 529 Fcε receptor I (FcεRi), 968, 969, 1870 following recovery from chemotherapy,
epidemiology, 527 FcγRIIIb, 2357 386, 388
etiology and pathogenesis, 527–528, 528f, FCGR1A, 1643 history of, 3–4
529f FCGR3A, 2357 FGA, 2151, 2154–2155, 2156, 2158, 2159
gene mutations, 527–528, 528t FCGR3B, 2357 FGB, 2151, 2156, 2158
gene therapy, 442 Fc receptors, 284, 1008, 1015–1016, 1053f, FGFR1, 958, 1279
laboratory features, 529 1058t FGFR3, 233t, 1735, 1736
therapy and course, 529–530 Fc receptor γ (FcRγ)-chain, 1869, 1879–1880, FGG, 2151, 2155, 2158, 2159
Fanconi genes, 442, 527, 528f, 528t 1880f FGL2 (fibrinogen-like protein 2), 1182
FAO (fatty acid oxidation), 198, 200 FcRI, in newborns, 107 FH (fumarate hydratase), 193
Farnesyltransferase inhibitors, for acute FDG-PET FH (dihydrofolate), 584
2
myelogenous leukemia, 1403 in diffuse large B-cell lymphoma staging, FH (dihydrofolate) reductase, 584
2
Fas (CD95), 210, 1224, 1564, 1873 1633 FH (tetrahydrofolate acid), 584, 586f
4
Fas-associated death domain (FADD), 204f, in Hodgkin lymphoma staging, 1608, FHL (familial hemophagocytic
205, 249, 302, 302f 1608f, 1611, 1613, 1617 lymphohistiocytosis), 1228, 1849,
Fasciitis, eosinophilic, 960 in myeloma staging, 1715, 1749–1750, 2061
Fascioliasis, 957t 1750f Fibrin
FAS-dependent pathway, in aplastic anemia, Febrile nonhemolytic transfusion reaction antithrombin activity, 2154
515 (FNHTR), 2375 degradation, 2303, 2310, 2310f. See also
Fas/Fas ligand system, 210, 1873 FECH, 897–898 Fibrinolysis
FAT (fatty acyl translocase). See Glycoprotein FECH (ferrochelatase, heme synthetase), in disseminated intravascular coagulation,
(GP)IV 893f, 895, 917 2201

Kaushansky_index_p2393-2506.indd 2432 9/21/15 3:21 PM